Defective Drugs:

Actos Linked to Bladder Cancer

ClassAction.org Alert
This Alert Affects:
Patients who were diagnosed with bladder cancer after taking any of the following diabetes drugs: Actos, ActoPlus Met, ActoPlus Met XR or Duetact.
Damages: An Actos bladder cancer lawsuit may provide patients the opportunity to seek compensation for damages including medical expenses, lost wages and pain and suffering.
Company(ies): Takeda Pharmaceuticals
Additional Details: Actos, ActoPlus Met, ActoPlus Met XR and Duetact contain pioglitazone, an oral diabetes medication which helps control blood sugar levels and has been linked to bladder cancer.
Date: The FDA issued an Actos and bladder cancer warning on June 15, 2011.
Get Help :
If you or someone you know has been affected by this product or service, submit your details for a free evaluation by completing the form on the right. There is no cost or obligation.

Actos

Actos

An Actos warning was released by the FDA on June 15, 2011 to inform the public that patients taking the Type 2 diabetes drug for longer than a year may have an increased risk of developing bladder cancer. The agency made this announcement, linking Actos and bladder cancer, after it had reviewed data which showed that patients with the longest exposure to the drug were put at a greater risk of bladder cancer. According to reports, the risk of bladder cancer among these patients was as high as 40%.

If you were diagnosed with bladder cancer after taking Actos, ActoPlus Met, ActoPlus Met XR or Duetact, you may be entitled to compensation. To find out if you are qualified, complete our no cost, no obligation case review form today.

Actos and Bladder Cancer

In releasing the bladder cancer warning, the FDA also cited data from a study conducted by the French National Health Insurance Plan. This study found that patients who had been exposed to Actos had a 22% increased risk of developing bladder cancer. Additionally, in patients who had taken the drug for more than a year, the risk was reportedly as high as 34%. Patients who had taken a cumulative dose exceeding 28,000 milligrams had the highest risk (75%) for bladder cancer. The possible risk of bladder cancer was found primarily in men.

In light of this research, doctors were advised not to prescribe Actos to patients with active bladder cancer or a history of the disease. It also warned that patients taking the drug should be on alert for signs which may indicate bladder cancer, such as:

  • Pain during urination
  • Abdominal or back pain
  • Blood in the urine
  • Strong urge to urinate 

If you were you diagnosed with bladder cancer after taking Actos, ActoPlus Met, ActoPlus Met XR or Duetact, you may have legal recourse to recover compensation for your damages and losses.

Filing a Bladder Cancer Lawsuit

Because the Actos manufacturer may have failed to warn patients about the risk of bladder cancer, patients who were diagnosed with bladder cancer after taking this medication may have legal recourse. A lawsuit would allow patients the opportunity to seek compensation for medical bills, pain and suffering and other damages resulting from their disease. If you or a loved one was diagnosed with bladder cancer after taking Actos, ActoPlus Met, ActoPlus Met XR or Duetact, complete our no risk, no cost case review today to find out if you may be eligible for monetary damages. 

Comments

Report a Complaint
Yes No
Yes I agree to the Class Action Disclaimers.
Click here to review.
1137 →

Spread The Word